At what enterprise value was PRODUCT LIFE acquired in 2024?

During the acquisition of PRODUCT LIFE by 21 INVEST / OAKLEY CAPITAL INVESTMENTS in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PRODUCT LIFE when it was acquired by 21 INVEST / OAKLEY CAPITAL INVESTMENTS?

The exact EV/EBITDA multiple for PRODUCT LIFE is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

What was the revenue of PRODUCT LIFE at the time of the deal?

The revenue of PRODUCT LIFE at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PRODUCT LIFE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PRODUCT LIFE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/productlife-valorisee-500meur-par-21-invest-et-oakley-2097768

← DATABASE

Home Database Healthcare & PharmaPRODUCT LIFE

05/2024

PRODUCT LIFE acquired by 21 INVEST & OAKLEY CAPITAL INVESTMENTS

FRANCE Healthcare Services EV 500M - 1.5b EUR

Context

21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest. The strategic roadmap was focused on transforming PLG into an undisputed global leader through massive international consolidation.

PRODUCT LIFE, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

ProductLife Group (PLG) is a specialized global provider of outsourcing and consulting services for the pharmaceutical and life sciences industries. The company focuses on the highly regulated segments of Regulatory Affairs and Pharmacovigilance, supporting drug manufacturers through the entire product lifecycle—from clinical development to market authorization and post-market safety monitoring.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2024	ARDIAN	MASCO GROUP	ITALY	Healthcare Services
06/2024	PERMIRA	PHARMACORD	UNITED STATES	Health Tech
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	CRO / Clinical Trials
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	CRO / Clinical Trials
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Health Tech
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services
11/2020	KERSIA	SOPURA	BELGIUM	Sterilization & Hygiene
10/2020	IK PARTNERS	KERSIA	FRANCE	Sterilization & Hygiene
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PRODUCT LIFE by 21 INVEST / OAKLEY CAPITAL INVESTMENTS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: 21 invest / oakley capital investments